Werewolf Therapeutics (HOWL) Long-Term Debt Issuances (2023 - 2024)
Werewolf Therapeutics (HOWL) posted quarterly Long-Term Debt Issuances of $30.0 million for Q2 2024, down 25.0% on a QoQ basis from $40.0 million in Q1 2023.
Werewolf Therapeutics (HOWL) Long-Term Debt Issuances (2023 - 2024) Analysis & Trends
Werewolf Therapeutics has reported Long-Term Debt Issuances for 2 years, with the latest figure at $30.0 million in Q2 2024.
- Long-Term Debt Issuances for Q2 2024 came in at $30.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $30.0 million (changed 0.0% YoY), and the FY2024 annual result was $30.0 million, down 25.0% from the prior year.
- Long-Term Debt Issuances eased to $30.0 million in Q2 2024, from $40.0 million in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $40.0 million in Q1 2023 and troughed at $30.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 30.00 Mn |
| Jun 30, 2024 | 30.00 Mn |
| Mar 31, 2023 | 40.00 Mn |
| Mar 31, 2023 | 40.00 Mn |